Legal Status Overview
Gray AreaMassachusetts has no peptide-specific law: the state legislature and the Massachusetts Board of Registration in Pharmacy have not enacted a statute or regulation that names 'peptides' or 'research chemicals' as their own legal category. Instead, peptides fall under the same general rules as any other drug substance in Massachusetts: the Board of Registration in Pharmacy's compounding regulations (247 CMR 10.00), which incorporate USP compounding standards, and the federal Food, Drug & Cosmetic Act's 503A (traditional compounding pharmacy) and 503B (outsourcing facility) framework administered by the FDA. Because compounds like BPC-157 and TB-500 are not FDA-approved drugs and are not on FDA's list of bulk substances permitted for 503A compounding, a Massachusetts-licensed pharmacy generally cannot lawfully compound them for human use, leaving them in a legal gray zone sold mainly as 'research use only' chemicals outside the prescription-drug supply chain. Semaglutide and tirzepatide, by contrast, are FDA-approved prescription drugs that can be prescribed in Massachusetts, though compounded (non-brand-name) versions of them are subject to the same shifting 503A/503B bulk-substance restrictions as in every other state.
Key Points
- Massachusetts has not enacted any statute, administrative code section, or Board of Pharmacy rule that specifically names 'peptides' or 'research chemicals' as a distinct legal category, based on a review of Massachusetts pharmacy regulations. [1]
- The Massachusetts Board of Registration in Pharmacy regulates all drug compounding in the state under 247 CMR 10.00, which governs pharmacy compounding practice and defers to USP and federal compounding standards rather than listing specific compounds like BPC-157 by name. [2]
- Under the federal FDCA framework that Massachusetts-licensed pharmacies must follow, a substance can only be compounded under Section 503A if it appears on the FDA's bulks list, and BPC-157 has been evaluated and is not currently included on that list because of unresolved safety concerns identified by FDA's nominated-substances review process. [3]
- FDA has issued a nationwide compounding risk communication warning that compounded products claiming to contain semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) are not the same as FDA-approved semaglutide and raise safety concerns, a warning that applies to Massachusetts pharmacies and prescribers along with every other state. [4]
- A person cannot lawfully buy or import unapproved research peptides like BPC-157 or TB-500 for personal human use in Massachusetts because they are not FDA-approved drugs and are not on the federal list of substances approved for compounding, meaning any supplier marketing them for human consumption or injection is operating outside the lawful prescription-drug and compounding system. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- No Massachusetts-specific bill, regulation, or Attorney General guidance addressing peptides or research chemicals by name was identified as having been introduced or enacted in the last several years, based on available searches of Massachusetts legislative and regulatory sources. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- FDA-approved GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) can be legally prescribed by licensed Massachusetts practitioners, including via telehealth consistent with Massachusetts telehealth prescribing rules, but compounded versions of these drugs are subject to tightening federal restrictions as commercial shortages resolve. [4]
- Massachusetts pharmacy law does not create a separate criminal penalty scheme for peptides; enforcement in Massachusetts instead flows through general pharmacy-licensing law (unlicensed practice of pharmacy, misbranded/adulterated drug provisions) and federal FDA enforcement against unapproved or mislabeled drug products. [2]
Peptide-by-peptide status in Massachusetts
| BPC-157 | BPC-157 is not an FDA-approved drug and is not on the FDA bulk drug substances list for 503A compounding, so no Massachusetts pharmacy can lawfully compound or dispense it for human use, leaving it to circulate only as an unapproved 'research use only' chemical. [3] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are FDA-approved prescription drugs that may be legally prescribed and dispensed in Massachusetts, but compounded (non-brand) versions of these drugs face the same federal restrictions on compounding bulk GLP-1 substances that FDA has applied nationwide since the brand-name shortages eased. [4] |
| TB-500 (Thymosin Beta-4) | TB-500 has no FDA approval and no specific Massachusetts statute addressing it, so it is governed only by the general rule that unapproved peptide substances cannot be lawfully compounded or marketed for human use in Massachusetts. |
| Human Growth Hormone (HGH/Somatropin) | Somatropin (HGH) is a federally controlled prescription drug under the Anabolic Steroids Control Act framework, and in Massachusetts it can only be legally dispensed with a valid prescription for an FDA-approved indication through a licensed pharmacy, consistent with the Board of Registration in Pharmacy's general dispensing rules. [2] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides in Massachusetts without a prescription?
No -- in Massachusetts, peptides that function as drugs (such as BPC-157, TB-500, or GLP-1 compounds) cannot be lawfully sold for human use without a prescription from a licensed practitioner, because Massachusetts pharmacy law and the federal FDA framework treat unapproved peptide products as outside the legal prescription-drug supply chain. [3]
Is it legal to bring BPC-157 or TB-500 into Massachusetts for personal use?
Personal importation of BPC-157 or TB-500 into Massachusetts is not clearly authorized because neither compound is FDA-approved or on the federal list of substances allowed for pharmacy compounding, so shipments marketed for human use risk being treated as unapproved or misbranded drugs under federal law. [3]
Can a telehealth doctor legally prescribe semaglutide or tirzepatide in Massachusetts?
Yes -- a licensed Massachusetts practitioner can prescribe FDA-approved semaglutide or tirzepatide via telehealth, but compounded (non-brand) versions of these GLP-1 drugs are increasingly restricted under the same federal 503A/503B bulk-substance rules that apply nationwide. [4]
What happens if a Massachusetts pharmacy compounds BPC-157 or similar research peptides?
A Massachusetts pharmacy that compounds BPC-157 or similar unapproved peptides risks state licensing discipline from the Board of Registration in Pharmacy and federal FDA enforcement, since the substance is not on FDA's approved bulks list for 503A compounding. [3]
Does Massachusetts have its own law specifically banning or regulating research peptides?
No -- Massachusetts has no statute or Board of Pharmacy rule that specifically names peptides or 'research chemicals' as a category; their status is determined entirely by general Massachusetts compounding/pharmacy law and the federal FDA drug-approval and compounding framework. [2]